LLY Stock Summary and Trading Ideas (Eli Lilly And Company | NYSE:LLY)

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly And Company trades on the NYSE stock market under the symbol LLY.

As of November 25, 2024, LLY stock price declined to $747.17 with 256,742 million shares trading.

LLY has a beta of 1.11, meaning it tends to be more sensitive to market movements. LLY has a correlation of 0.19 to the broad based SPY ETF.

LLY has a market cap of $709.30 billion. This is considered a Mega Cap stock.

Last quarter Eli Lilly And Company reported $11 billion in Revenue and $1.18 earnings per share. This fell short of revenue expectation by $-661 million and missed earnings estimates by -$.27.

In the last 3 years, LLY traded as high as $972.53 and as low as $231.87.

The top ETF exchange traded funds that LLY belongs to (by Net Assets): VTI, VOO, SPY, VUG, IVV.

LLY has underperformed the market in the last year with a price return of +26.4% while the SPY ETF gained +33.6%. LLY has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -21.6% and -10.0%, respectively, while the SPY returned +8.3% and +0.4%, respectively.

LLY support price is $731.89 and resistance is $764.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LLY shares will trade within this expected range on the day.